Reduced dietary fat intake may decrease breast cancer recurrence

December 16, 2006

Reducing dietary fat intake may decrease the chance of a breast cancer recurrence in women who have been treated for early-stage breast cancer, according to a randomized, phase III trial in the December 20 issue of the Journal of the National Cancer Institute.

The relationship between dietary fat intake and breast cancer is unclear, both for primary breast cancer development and breast cancer recurrence. Rowan T. Chlebowski, M.D., Ph.D., of the Los Angeles Biomedical Research Institute at the Harbor-University of California, Los Angeles Medical Center in Torrance, Calif., and his colleagues set out to determine whether a low-fat diet could prolong relapse-free survival in women with early-stage breast cancer.

Between February 1994 and January 2001, 2,437 women who had been treated for early-stage breast cancer were recruited from the Women's Intervention Nutrition Study (WINS). They were randomly assigned to a dietary intervention group (40%), or a control group (60%). The new study reports an analysis of all information collected as of October 31, 2003 with an average of 5 years of follow-up, when funding for the intervention ceased.

The goal of the dietary intervention was to reduce dietary fat to 15% of total calories. Women in the intervention group attended eight biweekly, 1-hour counseling sessions to learn about a low-fat eating plan, and they kept written records of their daily fat gram intake. Dieticians contacted or met with the women every 3 months, and participants could attend optional monthly dietary group sessions. Women in the control group met with a dietician when they started the trial and were contacted by dieticians every 3 months.

At the beginning of the study, both groups consumed similar amounts of calories from fat--56 to 57 grams of fat per day (about 30% of total calories). After 1 year, the women in the dietary intervention group were consuming an average of 33 g/day (20.3% of total calories) compared with 51 g/day (29.2% of total calories) in the control group. The difference between the two groups was maintained throughout the trial. Average body weight was similar before the trial started, but 5 years later, the women in the intervention group weighed an average of 6 pounds less than the women in the control group.

Ninety-six of 975 women (9.8%) in the intervention group had some form of relapse, compared with 181 of 1462 women (12.4%) in the control group. The researchers calculate that 38 women would need to adopt such a dietary fat reduction plan to prevent one breast cancer recurrence. "Women in the dietary intervention group had a 24% lower risk of relapse than those in the control group," the authors write.

Their data also suggest that women with hormone receptor-negative breast cancers may have had the most benefit from the dietary fat reduction, but those results weren't statistically significant and will require further confirmation. The authors plan to address these and other questions in ongoing follow-up studies of the women.

They caution that the study relied on self-reports of dietary fat intake. Also, the reduction in body weight in the dietary intervention group may have had an effect on breast cancer recurrence, rather than dietary fat intake on its own.

"The WINS results indicate that a lifestyle intervention designed to reduce dietary fat intake can be successfully implemented in women with early-stage, resected breast cancer receiving conventional cancer management in a multicenter clinical trial setting," the authors write.

In an editorial, Anne C.M. Thiebaut, Victor Kipnis, and colleagues at the National Cancer Institute highlight the study's limitations and note the questions that it raises. They also point out the difficulty of conducting clinical trials of such drastic lifestyle changes. "WINS demonstrates that such trials can be successfully conducted... The totality of this evidence will help us better understand the fat-breast cancer connection and ultimately provide more definitive public health recommendations," they write.
-end-
EMBARGOED FOR RELEASE: 16 DECEMBER 2006 12:30 EST

NOTE: This press release and the accompanying article are being made available early to correspond with a presentation at the San Antonio Breast Cancer Symposium.

Contacts:

Citations:

Note: The Journal of the National Cancer Institute is published by Oxford University Press and is not affiliated with the National Cancer Institute. Attribution to the Journal of the National Cancer Institute is requested in all news coverage. Visit the Journal online at http://jncicancerspectrum.oxfordjournals.org/.

Journal of the National Cancer Institute

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.